| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2007 | EP1742951A1 6,7-dihydroxy-8-phenyl-3,6,7,8-tetrahydro-chromeno[7, 8-d]imidazole derivatives and their use as gastric acid secretion inhibitors |
| 01/17/2007 | EP1742950A1 Pyrazolo[4,3-d] pyrimidines |
| 01/17/2007 | EP1742949A1 Novel-2-(piperazin-1-yl)-and-2-([1,4]diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, production and use thereof as medicament for the treatment of diabetes mellitus |
| 01/17/2007 | EP1742948A2 Bicyclic heterocycles as kinase inhibitors |
| 01/17/2007 | EP1742947A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof |
| 01/17/2007 | EP1742945A1 Substituted phenylamino-pyrimidines |
| 01/17/2007 | EP1742944A1 Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| 01/17/2007 | EP1742942A1 Phenylthioacetic acid derivatives and use thereof |
| 01/17/2007 | EP1742941A1 Novel saperconazole crystalline forms and related processes, pharmaceutical compositions and methods |
| 01/17/2007 | EP1742940A1 N-[6-(4-morpholinyl)-3-pyridinyl]-2-(tetrahydro-2h-pyran-4-yl)-n-[(1-{[phenyl]methyl}-4-piperidinyl)methyl] acetamide derivatives and related compounds as glyt1 transport inhibitors for the treatment of neurological disorders such as schizophrenia |
| 01/17/2007 | EP1742939A2 Novel alkyne compounds exhibiting an mch antagonistic effect and drugs containing said compounds |
| 01/17/2007 | EP1742938A1 Preparation of candesartan cilexetil in high purity |
| 01/17/2007 | EP1742937A2 Pyrrolopyrimidine derivatives for treating proliferative diseases |
| 01/17/2007 | EP1742936A2 Polycyclic pyridines as potassium ion channel modulators |
| 01/17/2007 | EP1742935A1 Polycyclic pyrazines as potassium ion channel modulators |
| 01/17/2007 | EP1742934A2 Piperidine derivatives as modulators of chemokine receptor ccr5 |
| 01/17/2007 | EP1742932A1 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
| 01/17/2007 | EP1742925A1 Substituted 5, 6, 7, 8-tetrahydro-pyrido[4, 3-d]pyrimidine-2-yl compounds and 5, 6, 7, 8-tetrahydro-quinazoline-2-yl compounds |
| 01/17/2007 | EP1742924A1 Calcilytic compounds |
| 01/17/2007 | EP1742923A1 Pyrazole phenyl derivatives as ppar activators |
| 01/17/2007 | EP1742922A1 Crystalline pyrazole derivative |
| 01/17/2007 | EP1742921A2 Pyrazole derivatives useful for the treatment of cancer |
| 01/17/2007 | EP1742920A2 Naphthalimide derivatives for the treatment of cancer |
| 01/17/2007 | EP1742919A2 Tetrahydropyranyl cyclopentyl 1-substituted and 1,1-disubstituted tetrahydroisoquinoline modulators of chemokine receptor activity |
| 01/17/2007 | EP1742916A1 Phenyl compounds and their use in the treatment of conditions mediated by the action of pge2 at the ep1 receptor |
| 01/17/2007 | EP1742915A2 Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulators of chemokine receptor activity |
| 01/17/2007 | EP1742914A1 Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
| 01/17/2007 | EP1742913A1 Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| 01/17/2007 | EP1742912A1 Novel androgens |
| 01/17/2007 | EP1742911A1 3,4-disubstituted maleimides for use as vascular damaging agents |
| 01/17/2007 | EP1742910A1 Process for forming amorphous atorvastatin calcium |
| 01/17/2007 | EP1742908A1 Non-nucleoside reverse transcriptase inhibitors |
| 01/17/2007 | EP1742907A2 Certain chemical entities, compositions, and methods |
| 01/17/2007 | EP1742904A2 Substituted enaminones, their derivatives and uses thereof |
| 01/17/2007 | EP1742903A1 Pentenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof |
| 01/17/2007 | EP1742902A1 Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof |
| 01/17/2007 | EP1742710A1 Stabilized ascorbic acid compositions and methods therefor |
| 01/17/2007 | EP1742707A2 Treatment of cns disorders using cns target modulators |
| 01/17/2007 | EP1742692A2 Anti-adhesion spraying |
| 01/17/2007 | EP1742680A1 Bone substitute compositions and method of use |
| 01/17/2007 | EP1742664A1 Permeation enhancing compositions for anticholinergic agents |
| 01/17/2007 | EP1742663A2 Compositions capable of facilitating penetration across a biological barrier |
| 01/17/2007 | EP1742662A2 Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases |
| 01/17/2007 | EP1742661A2 Lipid compositions and use thereof |
| 01/17/2007 | EP1742646A1 Functionalised siloxanes for scar tissue treatment |
| 01/17/2007 | EP1742645A1 Compressed pharmaceutical compositions comprising peg and electrolytes |
| 01/17/2007 | EP1742644A2 Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine |
| 01/17/2007 | EP1742643A2 Modulation of glucose-6-phosphatase translocase expression |
| 01/17/2007 | EP1742642A2 Phosphonate analogs of hiv integrase inhibitor compounds |
| 01/17/2007 | EP1742641A2 Methods and compositions for detecting and treating retinal diseases |
| 01/17/2007 | EP1742640A2 Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| 01/17/2007 | EP1742639A2 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| 01/17/2007 | EP1742638A1 Composition comprising a diuretic and/or cardiac glycoside for the treatment of dna viral infections of the eye |
| 01/17/2007 | EP1742637A2 Transcription factor modulating compounds and methods of use thereof |
| 01/17/2007 | EP1742636A2 Preparation for the treatment cancer |
| 01/17/2007 | EP1742635A2 Substituted organosulfur compounds and methods of using thereof |
| 01/17/2007 | EP1742634A1 Polycyclic pyrimidines as potassium ion channel modulators |
| 01/17/2007 | EP1742633A2 Use of c-kit inhibitors for treating fibrosis |
| 01/17/2007 | EP1742632A2 Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds |
| 01/17/2007 | EP1742631A1 Fluorinated 4-azasteroids as androgen receptor modulators |
| 01/17/2007 | EP1742630A2 Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| 01/17/2007 | EP1742629A2 Methods for treating alcoholism |
| 01/17/2007 | EP1742628A1 Alternative forms of the phosphodiesterase-4 inhibitor n-cyclopropyl-1-{3-¬(1-oxidopryidin-3-yl)ethynyl|phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide |
| 01/17/2007 | EP1742627A2 Pde4b inhibitors and uses therefor |
| 01/17/2007 | EP1742626A2 Compounds and methods for treating non-inflammatory pain using pparalpha agonists |
| 01/17/2007 | EP1742625A1 (r,r)-formoterol in combination with other pharmacological agents |
| 01/17/2007 | EP1742624A2 Dopamine-agonist combination therapy with sedatives for improving sleep quality |
| 01/17/2007 | EP1742623A2 2-methylthiazolidine-2,4-dicarboxylic acid-containing combination preparations |
| 01/17/2007 | EP1742622A1 Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas |
| 01/17/2007 | EP1742620A1 Method of making silicone pressure sensitive adhesives for delivering hydrophilic drugs using a silicone polyether |
| 01/17/2007 | EP1742618A1 Novel oral formulations of ospemifene |
| 01/17/2007 | EP1742617A2 Lozenge for delivery of dextromethorphan |
| 01/17/2007 | EP1742613A2 Crosslinked amine polymers |
| 01/17/2007 | EP1742610A1 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer |
| 01/17/2007 | EP1742608A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARϝ-TYPE RECEPTORS, THEIR PROCESS OF PREPARATION AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS |
| 01/17/2007 | EP1742535A2 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| 01/17/2007 | EP1742534A2 Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
| 01/17/2007 | EP1742530A2 Antimicrobial coating for inhibition of bacterial adhesion and biofilm formation |
| 01/17/2007 | EP1719524A9 Nuclear transfer promoter for rac protein and method of screening the same |
| 01/17/2007 | EP1694623A4 Practical, cost-effective synthesis of ubiquinones |
| 01/17/2007 | EP1694600A4 High efficiency fullerene-based radical scavengers |
| 01/17/2007 | EP1643990B1 Metronidazole-based green tinted topical pharmaceutical composition |
| 01/17/2007 | EP1603914B1 Compounds having activity at 5ht2c receptor and uses thereof |
| 01/17/2007 | EP1562489A4 Stabilized polyester/cyanoacrylate tissue adhesive formulation |
| 01/17/2007 | EP1546369A4 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 01/17/2007 | EP1545429A4 Methods and compositions for treatment of dermal conditions |
| 01/17/2007 | EP1542679B1 4-(3,5-dicyanophenoxy) pyrazole derivatives for use as transcriptase modulators in the treatment of i.a. hiv |
| 01/17/2007 | EP1537117B1 Benzotriazabicyclic derivatives and use thereof as beta-lactamase inhibitors and anti-bacterial agents |
| 01/17/2007 | EP1537110B1 Triazospiro compounds having nociceptin receptor affinity |
| 01/17/2007 | EP1532148B1 Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity |
| 01/17/2007 | EP1482925B1 5-(2-hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropl]-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy |
| 01/17/2007 | EP1480970B1 Quinoline derivatives |
| 01/17/2007 | EP1453852B1 Selective urokinase inhibitors |
| 01/17/2007 | EP1450762B1 Novel formulation |
| 01/17/2007 | EP1441667B1 Improved endoprosthetic device |
| 01/17/2007 | EP1400518B1 Heterocyclic compound derivatives and medicines |
| 01/17/2007 | EP1392309B1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| 01/17/2007 | EP1383751B1 Novel azoles having an insecticidal action |
| 01/17/2007 | EP1370259B1 Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 01/17/2007 | EP1345900B1 Guanidine and amidine derivatives as factor xa inhibitors |